THYMMUNE THERAPEUTICS INC
Cambridge, MA · Biotech · Private
Thymic epithelial progenitor cells (TEPs) derived from pluripotent stem cells for transplantation to restore T cell function in athymic patients
- Grants
- $4.2M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 18
- 0 granted · 18 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Development of a stem-cell derived thymic cell therapy to treat patients with athymia | $299,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a stem-cell derived thymic cell therapy to treat patients with athymia | $586,728 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a stem-cell derived thymic cell therapy to treat patients with athymia | $286,729 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a stem-cell derived thymic cell therapy to treat patients with athymia | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a stem-cell derived thymic cell therapy to treat patients with athymia | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a stem-cell derived thymic cell therapy to treat patients with athymia | $1,000,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2345 | GENOPLAN INC. | — | $4.2M |
| 2346 | LifeMine Therapeutics | — | $30M |
| 2347 | MEDICON, INC. | — | — |
| 2348 | THYMMUNE THERAPEUTICS INC | — | — |
| 2349 | OmniTier, Inc. | — | $4.0M |
| 2350 | Memento Medicines | — | $38M |
| 2351 | WindMIL Therapeutics | — | $45M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Thymic Cells And Methods Of Makingapplication
- Thymic Cell Compositions And Methods Of Use Thereofapplication
- Hypoimmune Engineering For Universal Ipsc-derived Cellsapplication
- Hypoimmune Engineering For Universal Ipsc-derived Cellsapplication
- Thymic Cell Compositions And Methods Of Makingapplication
- Thymic Cell Compositions And Methods Of Makingapplication
- Thymic Cells And Methods Of Makingapplication
- Thymic Cells And Methods Of Makingapplication
- Thymic Cell Compositions And Methods Of Use Thereofapplication
- Thymic Cells And Methods Of Makingapplication
- Methods For Generating Thymic Cellsapplication
- Methods For Generating Thymic Cellsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.